Abstract 11858: Combination Therapy with Finerenone and Empagliflozin by Baseline Risk of Liver Fibrosis in the CONFIDENCE Trial
Background: The liver is an important organ in cardio-kidney-metabolic (CKM) disease because of its essential roles in glucose homeostasis, cholesterol synthesis, and drug metabolism. We evaluated whether baseline liver fibrosis risk, estimated using the Fibrosis-4 (FIB-4) index, influenced treatment responses to es...